Gilead Sciences Inc
GILD
Company Profile
Business description
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
Contact
333 Lakeside Drive
Foster CityCA94404
USAT: +1 650 574-3000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
17,600
Stocks News & Analysis
personal-finance
US stock market outlook: tariffs are 2025's wild card
Macrodynamic tailwinds persist, but stocks are already priced to perfection. Will tariffs derail the market in 2025?
stocks
10 cheap US dividend-growth stocks to buy
The stocks of these companies with a history of dividend increases look undervalued today.
stocks
The 10 best US dividend shares
These undervalued stocks with reliable dividends are worth considering.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,372.40 | 31.40 | 0.38% |
CAC 40 | 7,593.87 | 38.00 | 0.50% |
DAX 40 | 22,496.98 | 71.15 | 0.32% |
Dow JONES (US) | 40,669.36 | 141.74 | 0.35% |
FTSE 100 | 8,494.85 | 31.39 | 0.37% |
HKSE | 22,119.41 | 111.30 | 0.51% |
NASDAQ | 17,446.34 | 14.98 | -0.09% |
Nikkei 225 | 36,509.44 | 464.06 | 1.29% |
NZX 50 Index | 12,148.60 | 245.29 | 2.06% |
S&P 500 | 5,569.06 | 8.23 | 0.15% |
S&P/ASX 200 | 8,152.10 | 25.90 | 0.32% |
SSE Composite Index | 3,279.03 | 7.62 | -0.23% |